focus -WSS

focus

author：explore 2025-09-03 14:39:43 - browse：36279

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Johnson & Johnson sued for allegedly overpaying for workers' drugs

focus

WSS

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Physician groups backed by private equity giant lobby on mergers

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Why Novartis is going to walk from its acquisition of MorphoSys

Problems with a popular proposal to regulate AI in health care

knowledge

focus

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The high personal cost of affirmative action for Black doctors

The cancer drug shortage isn’t new — and neither are the solutions

The CDC's new social media misinformation war

ChatGPT in medicine: STAT answers readers' burning questions

Lawsuit alleges UnitedHealth Group unit illegally denied claims

FDA approval of Sarepta Duchenne genetic therapy gives me hope

NIH launches clinical trials and new research office for long Covid

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The high personal cost of affirmative action for Black doctors

entertainment

Surgery pushed Ben Carson to fame

AstraZeneca stays mum on Medicare drug pricing negotiations

Unique patient identifier: Experts argue the benefits, pitfalls

Wildfire pollution widens asthma inequities on Long Island

5 important ways Henrietta Lacks changed medical science

Medicare Advantage plans can’t deny care with AI, CMS warns

Wikipedia

focus

hotspot

Wikipedia